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We describe three types of Pseudomonas aeruginosa pneumonia.
Case 1. P. aeruginosa was isolated from the blood and sputum of a 29-year-old male non-smoker who
developed severe community-acquired pneumonia (CAP). Piperacillin was initially effective, but fever
and lobular pneumonia with cavities developed seven days after discharge. Intravenous piperacillin/
tazobactam and tobramycin were administered for four weeks, followed by oral ciproﬂoxacin for two
weeks. He ﬁnally recovered, but developed recurrent CAP due to P. aeruginosa despite appropriate
antibiotic therapy and immunocompetent status.
Case 2. P. aeruginosa was isolated from the blood and sputum of a 57-year-old woman with renal
cancer who developed hospital-acquired pneumonia (HAP) after surgical treatment. She recovered after
meropenem administration for four weeks.
Case 3. A 67-year-old woman with systemic sclerosis and malignant lymphoma who was followed up
on an outpatient basis underwent immunosuppressive therapy. Thereafter, she developed pneumonia
and was admitted to our institution where P aeruginosa was isolated from blood and sputum samples.
Healthcare-associated pneumonia (HCAP) was diagnosed and effectively treated with tobramycin and
ciproﬂoxacin.
P. aeruginosa is not only a causative pathogen of HAP and HCAP, but possibly also of CAP.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Pseudomonas aeruginosa is a common nosocomial pathogen that
often causes pneumonia in hospitalized patients [1,2], most of
whom have underlying medical conditions or risk factors for
Pseudomonas infection. Although rare, case reports and reviews
have described healthy individuals who have developed
community-acquired pneumonia (CAP) caused by P. aeruginosa [3e
8] that is often rapidly progressive and fatal.
Here, we compared hospital-acquired (HAP) and healthcare-
associated (HCAP) pneumonia caused by P. aeruginosa, withntrol and Prevention, Osaka
a 565-0871, Japan. Tel.: þ81 6
.jp, sekimm-ngs@umin.ac.jp
Ltd. This is an open access article urapidly progressive P. aeruginosa CAP in a previously healthy 29-
year-old man.
Case report
Case 1
A previously healthy 29-year-old man presented at the emer-
gency room in June 2012 with acute pain around the right shoulder
and high fever accompanied by extreme fatigue that had persisted
for nine days. He had a medical history of mild sinusitis, but had
never smoked.
A physical examination indicated the following: temperature,
39.5 C; blood pressure, 111/50 mmHg and a respiratory rate of 28
breaths/min. A physical examination revealed crackles (rhonchi) at
the upper right lung and chest radiography indicated bilateral
opacities (Fig.1(A) and (B)). His initialWBC count was 26,400/L, and
C-reactive protein (CRP) was 20.0 mg/dL. P. aeruginosa was identi-
ﬁed in blood cultures and respiratory specimens and the minimumnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. Chest radiography and computed tomography images of a 29-year-old patient admitted with CAP in June 2012 and August 2012. Chest radiography and computed to-
mography images in June 2012 (A and B, respectively) show patchy airspace opacity in right upper lung lobe. Those acquired in August 2012 (C and D, respectively) show right upper
lobular pneumonia with cavity.
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oratory Standards Institute criteria revealed susceptibility to levo-
ﬂoxacin, piperacillin, ciproﬂoxacin and gentamicin. Rapid antigen
tests for inﬂuenza A and B virus were negative. Intravenous
piperacillin (4  3 g/day) for 19 days improved the chest X-ray
ﬁndings and the inﬂammatory markers, WBC (8900/L) and CRP
(0.9 mg/dL). Blood cultures also became negative. He was dis-
charged from hospital after completing the course of treatment.
However, he returned to the hospital two days later with high
fever. Chest radiography and CT revealed lobular pneumonia with
cavities and P. aeruginosa that was susceptible to most of the same
antibiotics as before was isolated from sputum once again. The
WBC count and CRP concentration at this point were 10,800/L and
11.6 mg/dL, respectively. Oral levoﬂoxacin (500 mg/day) for one
week improved chest radiography ﬁndings, WBC (7500/L) and CRP
(2.8 mg/dL).
One month thereafter, a chest X-ray and CT during August 2012
revealed worsened inﬁltration shadows around cavities (Fig. 1(C)
and (D)). Therefore, he was admitted for a third time, and treated
with intravenous piperacillin/tazobactam (3  4.5 g/day) and
tobramycin (300mg/day) for four weeks followed by 300mg/day of
oral ciproﬂoxacin for two weeks. The patient has since remained
free of further recurrence.
Case 2
A 57-year-old womanwith current renal cancer and a history of
smoking developed pneumonia seven days after a nephrectomy in
October 2012.
A physical examination revealed a temperature of 37.1 C, blood
pressure of 120/80 mmHg and crackles (rhonchi) in the left lung.
Chest radiography indicated inﬁltration shadows in the left lung
ﬁeld (Fig. 2(A) and (B)). Her initial WBC count was 720/L because
she was under chemotherapy, and CRP was 16.4 mg/dL. P.aeruginosa determined in blood cultures and respiratory specimens
was susceptible to meropenem, ciproﬂoxacin and gentamicin but
resistant to piperacillin. Intravenous meropenem (3  1 g/day) for
14 days followed by cefepime (3  1 g/day) for 10 days improved
the chest X-ray ﬁndings and the pneumonia.
Case 3
A 67-year-old woman with systemic sclerosis and malignant
lymphoma was admitted to the emergency room in March 2013
with dyspnea and disturbed consciousness. She was followed up as
an outpatient, and had recently been treated with rituximab and
oral prednisolone.
A physical examination indicated a temperature of 39.1 C and
blood pressure of 88/56 mmHg. A physical examination revealed
crackles (rhonchi) at the left lung. Chest radiography indicated
inﬁltration shadowsmainly in the left lower ﬁeld (Fig. 2(C) and (D)).
Saturated pulse oxygenwas 90% under an O2 10 L/minmask and the
patient was therefore placed on a respirator. Her initial WBC count
was 4900/L, and CRP was 27.8 mg/dL. P. aeruginosa determined in
blood cultures and respiratory specimens was susceptible to levo-
ﬂoxacin, piperacillin, ciproﬂoxacin and gentamicin. Intravenous
piperacillin/tazobactam (3  4.5 g/day) improved her status after
17 days.
Discussion
P. aeruginosa is an established causative pathogen of HAP and
HCA P [1], but CAP caused by this organism in previously healthy
individuals is rare. However, over ten occurrences of CAP have been
documented [3,8]. Rose [8] described chronic pneumonia due to
P. aeruginosa that developed in a 43-year-old man who had been
previously considered healthy, in contrast to the HAP and HCAP
caused by P. aeruginosa that develops in patients and which might
Fig. 2. Chest radiography and computed tomography images of a 57-year-old patient with HAP and a 67-year-old patient with HCAP. Chest radiography (A) and computed to-
mography (B) images of 57-year-old patient with HAP show inﬁltration shadow mainly in left upper lung ﬁeld. Those (C and D) of 67-year-old with HCAP show inﬁltration shadow
mainly in left lower lung ﬁeld.
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caused by P aeruginosa (Table 1) indicated that the features of CAP
caused by this pathogen differ from those of HAP and HCAP.
Huhulescu et al. also reported that community-acquired
P. aeruginosa infections are rare, tend to be mild and superﬁcial,
and tend to arise inmiddle-aged patients. Five patients described in
the literature were smokers [4]. The presentation can be variable,
with cough, pleuritic chest pain, fever and sputum production. Half
of all reported patients with sputum production had hemoptysis.
The 29-year-old patient described herein had chest pain and
fever, but no apparent underlying diseases and no history of
smoking. He was negative for HIV antibodies. CD4 and CD8 counts
and neutrophil functions such as phagocytosis and sterilizingTable 1
Comparison of three types of Pseudomonas aeruginosa pneumonia.
Patient 1 Patient 2 Patient 3
Category CAP HAP HCAP
Age 29 57 67
Comorbidity None Renal cancer Systemic sclerosis,
Malignant lymphoma
Severity
CURB65 Mild Moderate Severe
PSI 29 107 167
Chest X-ray <1/3 >2/3 Middle range
Cavity Yes Yes Yes
Shock No No Yes
Respirator No No Yes
WBC (cells/L) 26,000 720 4900
CRP (mg/dL) 20.0 16.4 27.8
Culture
Sputum Positive Positive Positive
Blood Positive Positive Positive
30-day Survival Survived Survived Survived
Drug resistance No Yes No
CAP, community-acquired pneumonia; HAP, hospital-acquired pneumonia; HCAP,
healthcare-associated pneumonia; PSI, pneumonia severity index.functions were normal (data not shown). The cause of P. aeruginosa
CAP remained unclear, but we considered that chronic sinusitis
might be involved. However, an otorhinolaryngeal specialist eval-
uated the sinusitis as mild and P. aeruginosa was not isolated from
nasal specimens.
One report suggests thatP. aeruginosaCAP shouldbe suspected in
patients with environmental risk factors and gram-negative bacilli
in sputum samples, and in those who present with pneumonia
accompanied by overwhelming sepsis [9]. Pneumonia caused by
P. aeruginosa has been associated with exposure to contaminated
aerosolized water. Examples include otitis externa, varicose ulcers
and folliculitis associated with Jacuzzis [10]. Our patient with CAP
was a clerk, he had not been exposed to aerosolized water and none
of his family and colleagues had similar symptoms.
Over 92% of CAP caused by P. aeruginosa patients have bacteremia,
and83%of themhaveP. aeruginosa in sputumspecimens.Althoughthe
mortality rate in one series was 33%, patients diedwithin amedian of
11 h from admission [3]. Of those who survived, only onewas treated
empirically upon admission with an antibiotic effective against Pseu-
domonas spp [3]. Therapy for the remaining survivors was directed by
positive culture results obtained at 1e3 days after admission.
The infections in our patients were not fatal, but pneumonia
with lung abscesses recurred despite the absence of underlying
diseases or immunocompromising factors in the patient with CAP.
He was then treated with levoﬂoxacin, which does not affect an-
aerobes that are major pathogens involved in abscesses [1,11]. He
might have been co-infected with anaerobes during the ﬁrst
episode, although anaerobes were not detected in any specimens,
including sputum and blood at the ﬁrst and subsequent admissions
in June and August (data not shown). Co-infection with
P. aeruginosa and anaerobes has been suggested in diabetic foot
infections, Fournier gangrene and paranasal sinus fungus balls [12e
14]. Fungi were also undetectable in all specimens from our patient.
P. aeruginosa pneumonia can be difﬁcult to treat because it tends
to resist the usual antibiotics recommended for treating CAP. Torres
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CAP due to P. aeruginosa also had bronchiectasis, suggesting that
patients with structural lung diseases should receive broader
therapy [15]. Both the American Thoracic Society and Canadian
guidelines for treating CAP recommend that patients with struc-
tural lung diseases who present with CAP should be given antibi-
otics that are effective against P. aeruginosa [11]. However, our
patient and others with P. aeruginosa CAP did not have underlying
diseases, including structural lung diseases. Kunimasa et al. isolated
P. aeruginosa from a patient with CAP who was similar to ours and
analyzed the organism in vivo using amouse pneumoniamodel and
in vitro using bioﬁlm production, but they could not explain how
such severe CAP developed in an otherwise healthy young man [6].
Further immunological and microbiological analyses of CAP caused
by P. aeruginosa are required.
In conclusion, we described three patients with P. aeruginosa
pneumonia including a 29-year-old man with CAP who had
otherwise been healthy except for a history of mild sinusitis.
Although he recovered with appropriate therapy, P. aeruginosa CAP
recurred with a lung abscess. Co-infection with anaerobes might
have been associated with this pathogenesis. Further studies of
host status and microbiological characteristics are required and
P. aeruginosa CAP should be carefully distinguished from HAP and
HCAP and appropriately treated.Acknowledgments
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